Clinical Trials Browser

Interventional × belzutifan × 90 days × Clear all

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 3 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07227402 2026-04-13

LITESPARK-033

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT07489495 2026-03-24

LITESPARK-034

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07049926 2026-03-20

MK-3475-03C

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT04586231 2026-03-05

MK-6482-011

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms